Bacteriophage Therapy in Tonsillitis

• Status: Active, not recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tashkent Pediatric Medical Institute

Criteria

Inclusion Criteria:

• children from 3 to 14 years old.

• children with sore throat.

• children diagnosed with acute tonsillitis.

• children diagnosed with acute respiratory infection (rhinitis, sinusitis, nasopharyngitis).

• children with the opportunity to visit the outpatient clinic.

• children with the ability to receive inhalation therapy.

• children from parents (or guardians) who have given written permission to conduct clinical and laboratory research.

Exclusion Criteria:

• children under 3 years old and over 14 years old.

• children receiving hospital treatment.

• children with acute respiratory tract diseases (bronchitis, pneumonia, pleurisy).

• children with сhronic respiratory tract diseases (bronchitis, pneumonia).

• children who are allergic to antibiotics.

• children with cancer, immunological and hematological diseases.

• children with severe psychological illnesses (schizophrenia, mental retardation, etc.)

• children with cancer, immunological and hematological diseases.

• children with tuberculosis.